Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib RWS in Solid Tumors
NCT05380986Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of camrelizumab and Rivoceranib in solid tumor, sponsored by Henan Cancer Hospital. Primary endpoint: Adverse Events at 2 years. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05380986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380986.